Triple Semicircular Canal Plugging Effective for Vertigo Control in Meniere Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 31, 2025 -- Triple semicircular canal plugging (TSCP) is effective for vertigo control but is associated with a risk for hearing loss in patients with Meniere disease (MD), according to a systematic review and meta-analysis published online Dec. 5 in PLOS ONE.
Jia quan Zhu, from Fengdu General Hospital in Chongqing, China, and colleagues conducted a meta-analysis involving 367 patients with MD from seven studies to examine the effects of TSCP on hearing. The studies reported on duration, follow-up time, hearing loss, and vertigo control outcomes in patients with MD.
The researchers found that TSCP efficiently alleviated vertigo with a rate of 99 percent and yielded a rate of hearing loss of 22 percent. In a subgroup analysis, for hearing loss, 14 and 24 percent of patients had disease duration of more than or less than 12 months, respectively. The corresponding rates of vertigo control were 100.0 and 99.0 percent. Hearing loss rates were 23 and 20 percent in studies with follow-up time of more than or less than 24 months, respectively. The corresponding rates for vertigo control were 99.0 and 99.0 percent. Disease duration and follow-up time had no significant impact on hearing loss or vertigo control rates.
"In MD patients who have failed to control the symptoms by conventional treatment or nondestructive surgery such as an endolymphatic capsule, TSCP can not only effectively relieve vertigo, but also preserve residual hearing in most patients," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-02-01 12:00
Read more
- Electronic Patient-Reported Outcome Monitoring System Beneficial
- Beginning to Smoke Before Age 15 Increases Risk for COPD
- Long COVID Severity Linked to White Blood Cell Count
- Patient Care Experience Worse After Private Equity Acquisition of Hospitals
- Vitamin Deficiencies Common in Type 2 Diabetes
- First U.S. Death From Bird Flu Reported in Louisiana
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions